Guardant Health (GH) Stock Price, News & Analysis

Company Overview

Guardant Health, Inc., a precision oncology company, provides blood and tissue tests, data sets, and analytics in the United States and internationally. The company provides Guardant360; Guardant360 LDT; Guardant360 CDx Test; Guardant360 Response Test; Guardant360 TissueNext Test; GuardantINFINITY Test; GuardantConnect, an integrated software-based solution designed for clinical and biopharmaceutical customers to connect patients tested with assays with actionable alterations with potentially relevant clinical studies; GuardantOMNI Test for advanced stage cancer; and GuardantINFORM, an in-silico research platform for tumor evolution and treatment resistance across various biomarker-driven cancers. It offers Shield Test; Guardant Reveal Test for adjuvant treatment selection in early-stage cancer patients; Smart Liquid Biopsy Platform; and Guardant Galaxy, an AI-backed digital pathology platform that helps improve cancer biomarker detection. In addition, the company offers development services, including companion diagnostic development and regulatory approval, clinical study setup, monitoring and maintenance, testing development and support, technologies licensing, and kits fulfillment. The company has a collaboration agreement with Illumina, Inc. for the sharing of specimen samples to advance cancer research. The company was incorporated in 2011 and is headquartered in Palo Alto, California.

Key Stats

• Today's Range: $41.32 to $44.10
• 50-Day Range: $35.84 to $49.94
• 52-Week Range: $15.81 to $50.89
• Volume: 1.29 million shs
• Average Volume: 2.16 million shs
• Market Capitalization: $5.37 billion
• P/E Ratio: N/A
• Dividend Yield: N/A
• Price Target: $48.95
• Consensus Rating: Buy

Guardant Health Stock Analysis - MarketRank™

Guardant Health scored higher than 86% of companies evaluated by MarketBeat, and ranked 157th out of 930 stocks in the medical sector. Scores are calculated by averaging available category scores, with extra weight given to analysis and valuation.

Analyst's Opinion

• Score: 3.5 / 5
• Analyst Rating: Buy

Consensus Rating

Guardant Health has received a consensus rating of Buy. The company's average rating score is 3.00, and is based on 20 buy ratings, no hold ratings, and no sell ratings.

Amount of Analyst Coverage

Guardant Health has been the subject of 11 research reports in the past 90 days, demonstrating strong analyst interest in this stock.

Earnings and Valuation

• Score: 0.6 / 5
• Proj. Earnings Growth: Growing

Earnings Growth

Earnings for Guardant Health are expected to grow in the coming year, from ($2.90) to ($2.84) per share.

Price to Earnings Ratio vs. the Market

The P/E ratio of Guardant Health is -12.22, which means that its earnings are negative and its P/E ratio cannot be compared to companies with positive earnings.

Price to Earnings Ratio vs. Sector

The P/E ratio of Guardant Health is -12.22, which means that its earnings are negative and its P/E ratio cannot be compared to companies with positive earnings.

Price to Book Value per Share Ratio

Guardant Health has a P/B Ratio of 32.46. P/B Ratios above 3 indicate that a company could be overvalued with respect to its assets and liabilities.

Short Interest

• Score: 2.0 / 5
• Short Interest Level: Bearish

Percentage of Shares Shorted

7.15% of the float of Guardant Health has been sold short.

Short Interest Ratio / Days to Cover

Guardant Health has a short interest ratio ("days to cover") of 3.6, which is generally considered an acceptable ratio of short interest to trading volume.

Change versus previous month

Short interest in Guardant Health has recently increased by 5.70%, indicating that investor sentiment is decreasing significantly.

Dividend

• Score: 0.0 / 5
• Dividend Strength: N/A

Dividend Yield

Guardant Health does not currently pay a dividend.

Dividend Growth

Guardant Health does not have a long track record of dividend growth.

Sustainability and ESG

• Score: 4.4 / 5
• Environmental Score: -0.52

Percentage of Shares Shorted

7.15% of the float of Guardant Health has been sold short.

Short Interest Ratio / Days to Cover

Guardant Health has a short interest ratio ("days to cover") of 3.6, which is generally considered an acceptable ratio of short interest to trading volume.

Change versus previous month

Short interest in Guardant Health has recently increased by 5.70%, indicating that investor sentiment is decreasing significantly.

News and Social Media

• Score: 3.3 / 5
• News Sentiment: 1.02

News Sentiment

Guardant Health has a news sentiment score of 1.02. This score is calculated as an average of sentiment of articles about the company over the last seven days and ranges from 2 (good news) to -2 (bad news). This is a higher news sentiment than the 0.58 average news sentiment score of Medical companies.

News Coverage This Week

MarketBeat has tracked 13 news articles for Guardant Health this week, compared to 7 articles on an average week.

Search Interest

15 people have searched for GH on MarketBeat in the last 30 days. This is an increase of 114% compared to the previous 30 days.

MarketBeat Follows

Only 6 people have added Guardant Health to their MarketBeat watchlist in the last 30 days. This is a decrease of 0% compared to the previous 30 days.

Company Ownership

• Score: 2.5 / 5
• Insider Trading: Selling Shares

Insider Buying vs. Insider Selling

In the past three months, Guardant Health insiders have sold more of their company's stock than they have bought. Specifically, they have bought $0.00 in company stock and sold $15,035.00 in company stock.

Percentage Held by Insiders

Only 5.50% of the stock of Guardant Health is held by insiders.

Percentage Held by Institutions

92.60% of the stock of Guardant Health is held by institutions. High institutional ownership can be a signal of strong market trust in this company.

GH Stock Analysis - Frequently Asked Questions

How have GH shares performed this year?

Guardant Health's stock was trading at $30.55 at the beginning of the year. Since then, GH shares have increased by 42.4% and is now trading at $43.49.
View the best growth stocks for 2025 here.

How were Guardant Health's earnings last quarter?

Guardant Health, Inc. (NASDAQ:GH) released its earnings results on Thursday, February, 20th. The company reported ($0.90) earnings per share for the quarter, missing the consensus estimate of ($0.75) by $0.15. The business earned $201.81 million during the quarter, compared to analysts' expectations of $192.50 million. Guardant Health had a negative net margin of 59.05% and a negative trailing twelve-month return on equity of 19,157.20%.

When did Guardant Health IPO?

Guardant Health (GH) raised $200 million in an initial public offering on Thursday, October 4th 2018. The company issued 12,500,000 shares at a price of $15.00-$17.00 per share. J.P. Morgan and BofA Merrill Lynch acted as the underwriters for the IPO and Cowen, Leerink Partners and William Blair were co-managers.

How do I buy shares of Guardant Health?

Shares of GH stock can be purchased through any online brokerage account. Popular online brokerages with access to the U.S. stock market include Charles Schwab, E*TRADE, Fidelity, and Vanguard Brokerage Services.

What other stocks do shareholders of Guardant Health own?

Based on aggregate information from My MarketBeat watchlists, some other companies that Guardant Health investors own include NVIDIA (NVDA), Meta Platforms (META), Broadcom (AVGO), Salesforce (CRM), Advanced Micro Devices (AMD), CrowdStrike (CRWD) and Adobe (ADBE).

Company Calendar

• Last Earnings: 2/20/2025
• Today: 4/02/2025
• Next Earnings (Estimated): 5/08/2025
• Fiscal Year End: 12/31/2025

Industry, Sector and Symbol

• Stock Exchange: NASDAQ
• Sector: Medical
• Industry: Medical laboratories
• Sub-Industry: Healthcare
• Current Symbol: NASDAQ:GH
• CIK: 1576280
• Web: www.guardanthealth.com
• Phone: (855) 698-8887
• Fax: 888-974-4258
• Employees: 1,790
• Year Founded: N/A

Price Target and Rating

• Average Stock Price Target: $48.95
• High Stock Price Target: $60.00
• Low Stock Price Target: $32.00
• Potential Upside/Downside: +12.6%
• Consensus Rating: Buy
• Rating Score (0-4): 3.00
• Research Coverage: 20 Analysts

Profitability

• EPS (Most Recent Fiscal Year): ($3.56)
• Trailing P/E Ratio: N/A
• Forward P/E Ratio: N/A
• P/E Growth: N/A
• Net Income: $-479,450,000.00
• Net Margins: -59.05%
• Pretax Margin: -74.02%
• Return on Equity: -19,157.20%
• Return on Assets: -25.96%

Debt

• Debt-to-Equity Ratio: N/A
• Current Ratio: 6.22
• Quick Ratio: 5.85

Sales & Book Value

• Annual Sales: $739.02 million
• Price / Sales: 7.26
• Cash Flow: N/A
• Price / Cash Flow: N/A
• Book Value: $1.34 per share
• Price / Book: 32.46

Miscellaneous

• Outstanding Shares: 123,421,000
• Free Float: 116,759,000
• Market Cap: $5.37 billion
• Optionable: Not Optionable
• Beta: 1.50